These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36191692)

  • 1. Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir.
    Rhee SY; Parkin N; Harrigan PR; Holmes S; Shafer RW
    Antiviral Res; 2022 Dec; 208():105427. PubMed ID: 36191692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.
    Tao K; Rhee SY; Chu C; Avalos A; Ahluwalia AK; Gupta RK; Jordan MR; Shafer RW
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766338
    [No Abstract]   [Full Text] [Related]  

  • 5. A systematic review of the genetic mechanisms of dolutegravir resistance.
    Rhee SY; Grant PM; Tzou PL; Barrow G; Harrigan PR; Ioannidis JPA; Shafer RW
    J Antimicrob Chemother; 2019 Nov; 74(11):3135-3149. PubMed ID: 31280314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
    Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
    J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
    Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
    J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.
    Ndashimye E; Li Y; Reyes PS; Avino M; Olabode AS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Barr SD; Arts EJ
    J Antimicrob Chemother; 2021 Oct; 76(11):2965-2974. PubMed ID: 34453542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
    Vavro C; Ruel T; Wiznia A; Montañez N; Nangle K; Horton J; Buchanan AM; Stewart EL; Palumbo P
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164521. PubMed ID: 34694878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
    J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
    Hassounah SA; Liu Y; Quashie PK; Oliveira M; Moisi D; Brenner BG; Sandstrom PA; Mesplède T; Wainberg MA
    J Virol; 2015 Dec; 89(23):12002-13. PubMed ID: 26378179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
    Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
    J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
    Xiao MA; Cleyle J; Yoo S; Forrest M; Krullaars Z; Pham HT; Mesplède T
    Antimicrob Agents Chemother; 2023 May; 67(5):e0138622. PubMed ID: 37071019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
    Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
    J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.
    Quashie PK; Mesplède T; Han YS; Veres T; Osman N; Hassounah S; Sloan RD; Xu HT; Wainberg MA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6223-35. PubMed ID: 24080645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants.
    Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.